Kenta Masui, M.D., Ph.D. - Publications

Molecular Pathology Ludwig Institute for Cancer Research, San Diego, CA, United States 

31 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Masui K, Harachi M, Ikegami S, Yang H, Onizuka H, Yong WH, Cloughesy TF, Muragaki Y, Kawamata T, Arai N, Komori T, Cavenee WK, Mischel PS, Shibata N. mTORC2 links growth factor signaling with epigenetic regulation of ironĀ metabolism in glioblastoma. The Journal of Biological Chemistry. PMID 31712311 DOI: 10.1074/jbc.RA119.011519  0.4
2019 Masui K, Onizuka H, Cavenee WK, Mischel PS, Shibata N. Metabolic reprogramming in the pathogenesis of glioma: Update. Neuropathology : Official Journal of the Japanese Society of Neuropathology. PMID 30609184 DOI: 10.1111/neup.12535  0.4
2018 Harachi M, Masui K, Okamura Y, Tsukui R, Mischel PS, Shibata N. mTOR Complexes as a Nutrient Sensor for Driving Cancer Progression. International Journal of Molecular Sciences. 19. PMID 30347859 DOI: 10.3390/ijms19103267  0.4
2017 Masui K, Kato Y, Sawada T, Mischel PS, Shibata N. Molecular and Genetic Determinants of Glioma Cell Invasion. International Journal of Molecular Sciences. 18. PMID 29207533 DOI: 10.3390/ijms18122609  0.4
2017 Gu Y, Albuquerque CP, Braas D, Zhang W, Villa GR, Bi J, Ikegami S, Masui K, Gini B, Yang H, Gahman TC, Shiau AK, Cloughesy TF, Christofk HR, Zhou H, et al. mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT. Molecular Cell. PMID 28648777 DOI: 10.1016/j.molcel.2017.05.030  0.4
2016 Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, Liu F, Hon GC, et al. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. PMID 27746144 DOI: 10.1016/j.ccell.2016.09.008  0.4
2016 Masui K, Shibata N, Cavenee WK, Mischel PS. mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. PMID 27427440 DOI: 10.1002/bies.201600026  0.4
2016 Masui K, Cavenee WK, Mischel PS. Cancer metabolism as a central driving force of glioma pathogenesis. Brain Tumor Pathology. PMID 27295313 DOI: 10.1007/s10014-016-0265-5  0.4
2016 Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, et al. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell. 29: 563-73. PMID 27070703 DOI: 10.1016/j.ccell.2016.03.012  0.48
2016 Masui K, Mischel PS, Reifenberger G. Molecular classification of gliomas. Handbook of Clinical Neurology. 134: 97-120. PMID 26948350 DOI: 10.1016/B978-0-12-802997-8.00006-2  0.4
2015 Masui K, Cavenee WK, Mischel PS. mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment. Brain Pathology (Zurich, Switzerland). 25: 755-9. PMID 26526943 DOI: 10.1111/bpa.12307  0.48
2015 Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavenee WK, Mischel PS. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proceedings of the National Academy of Sciences of the United States of America. PMID 26170313 DOI: 10.1073/pnas.1511759112  0.48
2015 Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, Kyotani K, Mizowaki T, Imahori T, Ejima Y, Masui K, Gini B, Yang H, Hosoda K, Sasaki R, et al. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. The Journal of Clinical Investigation. 125: 1591-602. PMID 25798620 DOI: 10.1172/JCI78239  0.48
2014 Masui K, Cavenee WK, Mischel PS. mTORC2 in the center of cancer metabolic reprogramming. Trends in Endocrinology and Metabolism: Tem. 25: 364-73. PMID 24856037 DOI: 10.1016/j.tem.2014.04.002  0.48
2014 Masui K, Cavenee WK, Mischel PS. mTORC2 dictates Warburg effect and drug resistance. Cell Cycle (Georgetown, Tex.). 13: 1053-4. PMID 24583874 DOI: 10.4161/cc.28377  0.48
2014 Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (New York, N.Y.). 343: 72-6. PMID 24310612 DOI: 10.1126/science.1241328  0.48
2013 Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metabolism. 18: 726-39. PMID 24140020 DOI: 10.1016/j.cmet.2013.09.013  0.48
2013 Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, et al. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5722-32. PMID 24030701 DOI: 10.1158/1078-0432.CCR-13-0527  0.48
2013 Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, Zhu S, Gu Y, Villa GR, Akhavan D, Nathanson D, Gini B, Mareninov S, Li R, Camacho CE, et al. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metabolism. 17: 1000-8. PMID 23707073 DOI: 10.1016/j.cmet.2013.04.013  0.48
2013 Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, Cavenee WK. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis. 34: 725-38. PMID 23455378 DOI: 10.1093/carcin/bgt086  0.48
2012 Masui K, Cloughesy TF, Mischel PS. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathology and Applied Neurobiology. 38: 271-91. PMID 22098029 DOI: 10.1111/j.1365-2990.2011.01238.x  0.48
2012 Honda H, Sasaki K, Minaki H, Masui K, Suzuki SO, Doh-Ura K, Iwaki T. Protease-resistant PrP and PrP oligomers in the brain in human prion diseases after intraventricular pentosan polysulfate infusion. Neuropathology : Official Journal of the Japanese Society of Neuropathology. 32: 124-32. PMID 21801238 DOI: 10.1111/j.1440-1789.2011.01245.x  0.48
2012 Masui K, Nakata Y, Fujii N, Iwaki T. Extensive distribution of glial cytoplasmic inclusions in an autopsied case of multiple system atrophy with a prolonged 18-year clinical course. Neuropathology : Official Journal of the Japanese Society of Neuropathology. 32: 69-76. PMID 21615514 DOI: 10.1111/j.1440-1789.2011.01222.x  0.48
2011 Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, Popescu R, Della Donna L, Evers P, Dekmezian C, Reue K, Christofk H, Mischel PS, Pajonk F. Metabolic state of glioma stem cells and nontumorigenic cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 16062-7. PMID 21900605 DOI: 10.1073/pnas.1106704108  0.48
2011 Torisu R, Suzuki SO, Masui K, Yoshimoto K, Mizoguchi M, Hashizume M, Canoll P, Goldman JE, Sasaki T, Iwaki T. Persistent roles of signal transduction of platelet-derived growth factor B in genesis, growth, and anaplastic transformation of gliomas in an in-vivo serial transplantation model. Brain Tumor Pathology. 28: 33-42. PMID 21210235 DOI: 10.1007/s10014-010-0006-0  0.48
2011 Masui K, Suzuki SO, Hashiguchi K, Morioka T, Yoshiura T, Sasaki T, Iwaki T. Focal cortical dysplasia coexisting with diffuse astrocytoma in childhood: a case report and reappraisal of the glial component in archival FCD cases. Neuropathology : Official Journal of the Japanese Society of Neuropathology. 31: 433-9. PMID 21118400 DOI: 10.1111/j.1440-1789.2010.01173.x  0.48
2011 Seki Y, Suzuki SO, Masui K, Harada S, Nakamura S, Kanba S, Iwaki T. A simple and high-yield method for preparation of rat microglial cultures utilizing Aclar plastic film. Neuropathology : Official Journal of the Japanese Society of Neuropathology. 31: 215-22. PMID 21092060 DOI: 10.1111/j.1440-1789.2010.01163.x  0.48
2010 Yamaguchi S, Suzuki SO, Matsuo Y, Uesaka T, Matsukado K, Masui K, Iwaki T. Large hypothalamic hamartoma with calcification and cystic components in an adult--case report. Neurologia Medico-Chirurgica. 50: 495-8. PMID 20587978 DOI: JST.JSTAGE/nmc/50.495  0.48
2010 Masui K, Suzuki SO, Torisu R, Goldman JE, Canoll P, Iwaki T. Glial progenitors in the brainstem give rise to malignant gliomas by platelet-derived growth factor stimulation. Glia. 58: 1050-65. PMID 20468047 DOI: 10.1002/glia.20986  0.48
2010 Masui K, Suzuki SO, Kondo A, Iwaki T. A 6-year-old girl with an extra-axial mass in the middle cranial fossa. Brain Pathology (Zurich, Switzerland). 20: 269-72. PMID 20438488 DOI: 10.1111/j.1750-3639.2009.00348.x  0.48
2008 Masui K, Mawatari SY, Suzuki SO, Iwaki T. Evaluation of sensitivity and specificity of doublecortin immunostatining for the detection of infiltrating glioma cells. Brain Tumor Pathology. 25: 1-7. PMID 18415660 DOI: 10.1007/s10014-007-0225-1  0.48
Show low-probability matches.